BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
BioRestorative Therapies, Inc. will report its first quarter 2024 financial results on May 14, 2024, after market close. The company will discuss a new commercial agreement and provide updates on its Phase 2 clinical trial in Spine and preclinical development program in Obesity. CEO Lance Alstodt will host the quarterly conference call to review the financial results and business progress.
BioRestorative Therapies announcing transformative commercial partnership with Cartessa.
Significant progress in clinical and preclinical development programs.
- None.
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity -
MELVILLE, N.Y., April 30, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it will release its first quarter 2024 financial results after market close on Tuesday, May 14, 2024.
"I look forward to providing more detail on our exciting recently announced transformative commercial partnership with Cartessa, as well as discussing the meaningful progress we are making with our clinical and preclinical development programs, during this, our first-ever quarterly conference call,” said Lance Alstodt, BioRestorative’s CEO.
Following the announcement, BioRestorative management will host its inaugural quarterly conference call to review the financial results and provide a business update.
First Quarter 2024 Results Conference Call Details:
Date: | Tuesday, May 14, 2024 |
Time: | 4:30 p.m. ET |
Domestic: | 1-888-506-0062 |
International: | 1-973-528-0011 |
Access Code: | 357232 |
Participants are asked to dial in approximately 10 minutes before the conference call is scheduled to begin. The call can also be accessed via webcast on the Company's website at https://www.biorestorative.com/investor-relations under “Events.” The webcast will be archived and accessible for approximately 90 days.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Email: ir@biorestorative.com
![](https://ml.globenewswire.com/media/NDk3ZDNmYzEtZjJlZS00ODM5LTk3ZmItZjYzZDU1Mzc3NGI4LTUwMDA4MDA0MA==/tiny/BioRestorative-Therapies-Inc.png)
FAQ
When will BioRestorative Therapies report its first quarter 2024 financial results?
What will be discussed during BioRestorative Therapies' quarterly conference call?
Who will host BioRestorative Therapies' quarterly conference call?